Shandong Boan Biotechnology Co (HKSE:06955) FCF Yield %: -13.11 (As of Sep. 09, 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

HKSE:06955 Shandong Boan Biotechnology Co Ltd HKSE:06955
42 GF Score
Price HK$2.86
GF Value HK$16.69
Valuation Possible Value Trap
! 4 Warning Signs
View Full Analysis

What is Shandong Boan Biotechnology Co FCF Yield %?

Shandong Boan Biotechnology Co HKSE:06955 -7.75% 42 FCF Yield % is -13.11 as of Sep. 09, 2026. GuruFocus rates HKSE:06955 with a GF Score™ of 42/100 and a GF Value™ of HK$16.69 (Possible Value Trap). The stock has 4 warning signs investors should review. Among 1,406 Biotechnology companies, Shandong Boan Biotechnology Co ranks worse than 57.68% on this metric.

FCF Yield % is calculated as Free Cash Flow divided by Market Capitalization. It is a financial solvency ratio that compares the free cash flow a company is expected to earn against its market value.

As of today, Shandong Boan Biotechnology Co's Trailing 12-Month Free Cash Flow is HK$-231.0 Mil, and Market Cap is HK$1,762.8 Mil. Therefore, Shandong Boan Biotechnology Co's FCF Yield % for today is -13.11%.

The historical rank and industry rank for Shandong Boan Biotechnology Co's FCF Yield % or its related term are showing as below:

HKSE:06955' s FCF Yield % Range Over the Past 10 Years
Min: -13.42   Med: -6.74   Max: -4.23
Current: -13.11


During the past 6 years, the highest FCF Yield % of Shandong Boan Biotechnology Co was -4.23%. The lowest was -13.42%. And the median was -6.74%.

HKSE:06955's FCF Yield % is ranked worse than
57.68% of 1406 companies
in the Biotechnology industry
Industry Median: -9.15 vs HKSE:06955: -13.11

Shandong Boan Biotechnology Co's FCF Margin % for the quarter that ended in Dec. 2025 was -52.59%.


Shandong Boan Biotechnology Co FCF Yield % Explanation

Similar to Earnings Yield %, FCF Yield % is financial solvency ratio. A lower ratio suggests a less attractive investment, indicating that investors might not receive substantial returns in proportion to their investment. Conversely, a high free cash flow yield signals that a company generates sufficient cash to comfortably meet its debts, obligations, and dividend payments, making it a promising investment choice.


Shandong Boan Biotechnology Co FCF Yield % Related Terms


Shandong Boan Biotechnology Co FCF Yield % Historical Data

* Premium members only.

The historical data trend for Shandong Boan Biotechnology Co's FCF Yield % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Shandong Boan Biotechnology Co FCF Yield % Chart

Shandong Boan Biotechnology Co Annual Data
Trend Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
FCF Yield %
Get a 7-Day Free Trial 0.00 -4.52 -4.34 -10.29 -4.37

Shandong Boan Biotechnology Co Semi-Annual Data
Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24 Dec24 Jun25 Dec25 Jun26
FCF Yield % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only -13.35 -7.78 -0.11 -8.60 0.00

HKSE:06955 vs VRTX, REGN, MRNA: FCF Yield % Comparison

For the Biotechnology subindustry, Shandong Boan Biotechnology Co's FCF Yield %, along with its competitors' market caps and FCF Yield % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Shandong Boan Biotechnology Co FCF Yield % vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Shandong Boan Biotechnology Co's FCF Yield % distribution charts can be found below:

* The bar in red indicates where Shandong Boan Biotechnology Co's FCF Yield % falls into.


HKSE:06955
42GF Score
Shandong Boan Biotechnology Co Ltd HKSE:06955
FCF Yield % is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Shandong Boan Biotechnology Co FCF Yield % Calculation

FCF Yield % is a financial solvency ratio that compares the free cash flow a company is expected to earn against its market value.

Shandong Boan Biotechnology Co's FCF Yield % for the fiscal year that ended in Dec. 2025 is calculated as

FCF Yield %=Free Cash Flow / Market Cap
=-231.062 / 5289.839
=-4.37%

Shandong Boan Biotechnology Co's annualized FCF Yield % for the quarter that ended in Dec. 2025 is calculated as

FCF Yield %=Free Cash Flow * Annualized Factor / Market Cap
=-227.383 * 2 / 5289.839
=-8.60%

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about FCF Yield % →
What does a FCF Yield % of -13.11 mean?
Shandong Boan Biotechnology Co (HKSE:06955) has a FCF Yield % of -13.11 as of Sep. 09, 2026. FCF Yield is calculated as Free Cash Flow divided by Market Capitalization. View historical data on Shandong Boan Biotechnology Co and its competitors. According to the industry distribution chart, Shandong Boan Biotechnology Co ranks #811 out of 1406 companies in the Biotechnology industry, placing it in the top 57.7%.
Is Shandong Boan Biotechnology Co's FCF Yield % too high?
Shandong Boan Biotechnology Co's current FCF Yield % is -13.11. Based on the distribution chart, Shandong Boan Biotechnology Co ranks #811 out of 1406 companies in the Biotechnology industry, which is below the industry midpoint. Overall, Shandong Boan Biotechnology Co has a GF Score™ of 42/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does Shandong Boan Biotechnology Co's FCF Yield % compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Shandong Boan Biotechnology Co ranks #811 out of 1406 companies for FCF Yield %. This places Shandong Boan Biotechnology Co in the lower half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good FCF Yield % for a Biotechnology company?
A good FCF Yield % depends on the Biotechnology industry context. However, FCF Yield % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high FCF Yield % mean?
A high FCF Yield % can signal that a stock is expensive relative to its fundamentals. FCF Yield is calculated as Free Cash Flow divided by Market Capitalization. View historical data on Shandong Boan Biotechnology Co and its competitors. Shandong Boan Biotechnology Co's current FCF Yield % is -13.11. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Shandong Boan Biotechnology Co stock overvalued right now?
Based on GuruFocus' analysis, Shandong Boan Biotechnology Co (HKSE:06955) is currently considered Possible Value Trap. The stock's GF Value™ is HK$16.69, compared to a current price of HK$2.86 — trading 82.9% below its estimated fair value. The current FCF Yield % is -13.11. Shandong Boan Biotechnology Co's overall GF Score™ is 42/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is FCF Yield % calculated?
FCF Yield % is calculated from a company's financial statements. For Shandong Boan Biotechnology Co (HKSE:06955), the current FCF Yield % is -13.11 as of Sep. 09, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Shandong Boan Biotechnology Co (HKSE:06955) Overvalued in 2026?

Based on GuruFocus' analysis, Shandong Boan Biotechnology Co stock appears to be undervalued. The current stock price of HK$2.86 is trading 82.9% below its estimated GF Value™ of HK$16.69. GuruFocus considers Shandong Boan Biotechnology Co to be Possible Value Trap.

Key valuation signals for HKSE:06955:

  • FCF Yield %: -13.11
  • GF Value™: HK$16.69 vs. price of HK$2.86 (82.9% below fair value)
  • GF Score™: 42/100 with 4 warning signs

No single metric tells the full story. See the HKSE:06955 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Shandong Boan Biotechnology Co Business Description

Address No. 39 Keji Avenue, High-Tech Industrial Development Zone, Shandong Province, Yantai, CHN
Shandong Boan Biotechnology Co Ltd is a fully integrated biopharmaceutical company. It is focused on developing, manufacturing, and marketing biologics, with a focus on oncology, autoimmune diseases, ophthalmology, and metabolic diseases. The company's drug discovery activities revolve around multiple platforms: Fully Human Antibody Platform, bsAb/msAb/Probody Platform, and ADC Platform. It has commercialized several products, such as Boyounuo, Boyoubei (denosumab injection 60 mg), Boluojia (denosumab injection 120 mg), Boyouping (dulaglutide injection), and Boyoujing; and is actively engaged in the development of other drugs like BA1104 (nivolumab injection), BA1106, BA1302 (an anti-CD228 ADC), etc. Geographically, the company generates maximum revenue from the Chinese mainland.
42GF Score

Get the complete analysis for HKSE:06955

FCF Yield % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

HK$2.86
Price
HK$16.69
GF Value